Cancer gene therapy is a technique used for the treatment of cancer where therapeutic DNA is being introduced into the gene of the patient with cancer. The increasing prevalence of cancer is one of the key reasons that boost the growth of the global Cancer Gene Therapy market. According to National Cancer Institute, Cancer is among the leading causes of death worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.5 million and the number of cancer-related deaths to 16.4 million.
Currently, CAR T-cell use has gathered significant attention from the sponsors following the exhibition of its huge potential in the treatment of several diseases. The promising future of CAR T-cell is projected to intensify the growth opportunities of the global gene therapy market. Furthermore, noteworthy progress has been made in the fields of cellular and molecular biology is expected to enlarge the growth of the global gene therapy market in the coming years. Moreover, rapid technological development made in the gene-editing and genomics tools is further projected to hike the demand for gene therapy. Eventually it fuel the growth of the market.
However, the high treatment cost is a major barrier to the growth of the cancer gene therapy market. Additionally, rising government funding and initiatives, growth in the pipeline of cancer gene therapy products, and collaborations to develop and launch gene-therapy products are some other important factors remarkably propelling the growth of the Cancer Gene Therapy market.
Covid-19 Impact on Cancer Gene Therapy Market:
In addition, the current Cancer Gene Therapy Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Cancer Gene Therapy Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Cancer Gene Therapy Market Segment Overview
Based on therapy, the Gene Transfer segment has significant growth in the global Cancer Gene Therapy market. Gene transfer is a new treatment modality that introduces new genes into a cancerous cell or the surrounding tissue to cause cell death or slow the growth of cancer. This treatment technique is very flexible, and a wide range of genes and vectors are being used in clinical trials with successful outcomes. As these therapies mature, they may be used alone or in combination with current treatments to help make cancer a manageable disease.
Cancer Gene Therapy Market, By Therapy
- Gene Induced Immunotherapy
- Delivery of Cytokines Gene
- Delivery of Tumor Antigen Gene
- Oncolytic Virotherapy
- Adenovirus
- Lentivirus
- Retro Virus
- Adeno Associated Virus
- Herpes Simplex Virus
- Alpha Virus
- Vaccinia Virus
- Simian Virus
- Others
- Gene Transfer
- Naked/Plasmid Vectors
- Electroporation
- Sonoportion
- Magnetofection
- Gene Gun
· Hospitals
· Diagnostics Centers
· Research Institutes
Cancer Gene Therapy Market Regional Overview
In terms of region, North America is projected to hold the largest share of the global Cancer Gene Therapy market. The U.S. is the prominent market for cancer gene therapy due to its increased funding for research & development and other government initiatives. Moreover, other factors such as the rising demand for DNA vaccines and the increasing interest of venture capitalists to invest in the commercialization of gene-based cancer therapies are expected to boost the market in this region. Similarly, the market in Asia-Pacific is expected to witness significant growth during the forecast period. China's cancer gene therapy is estimated to attribute for largest revenue, due to the recent launch of Gendicine and growing healthcare expenditure. This prime factor contributes significantly to the market’s expansion in this region.
Cancer Gene Therapy Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Cancer Gene Therapy Market Competitor overview
Some key developments and strategies adopted by manufacturers in Cancer Gene Therapy are highlighted below.
· In July 2021, OncoSec Medical Inc. will evaluate its DNA-plasmid interleukin-12 (IL-12) TAVO (tavokinogene telseplasmid) with Merck & Co Inc's Keytruda (pembrolizumab) in KEYNOTE-C87 Phase 3 trial. The planned trial will evaluate the overall survival of patients treated with the TAVO / Keytruda combination versus standard of care in late-stage patients with metastatic melanoma who are refractory to immune checkpoint therapy.
Cancer Gene Therapy Market, Key Players
· Adaptimmune
· ZioPharm Oncology Altor Bioscience
· MolMed
· bluebird bio
· Shanghai Sunway Biotech company limited
· MultiVir
· Shenzhen SiBiono GeneTech, Corporation
· GlaxoSmithKline
· Merck
· Celgene
· BioCancell
· SynerGene Therapeutics
· OncoGenex Pharmaceuticals
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Cancer Gene Therapy Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Therapy
- 5.2.1. Gene Induced Immunotherapy
- 5.2.1.1. Delivery of Cytokines Gene
- 5.2.1.2. Delivery of Tumor Antigen Gene
- 5.2.2. Oncolytic Virotherapy
- 5.2.2.1. Adenovirus
- 5.2.2.2. Lentivirus
- 5.2.2.3. Retro Virus
- 5.2.2.4. Adeno Associated Virus
- 5.2.2.5. Herpes Simplex Virus
- 5.2.2.6. Alpha Virus
- 5.2.2.7. Vaccinia Virus
- 5.2.2.8. Simian Virus
- 5.2.2.9. Others
- 5.2.3. Gene Transfer
- 5.2.3.1. Naked/Plasmid Vectors
- 5.2.3.2. Electroporation
- 5.2.3.3. Sonoportion
- 5.2.3.4. Magnetofection
- 5.2.3.5. Gene Gun
- 5.2.1. Gene Induced Immunotherapy
- 5.3.1. Hospitals
- 5.3.2. Diagnostics Centers
- 5.3.3. Research Institutes
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America, Middle East and Africa
6. North America Cancer Gene Therapy Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Therapy
- 6.2.1. Gene Induced Immunotherapy
- 6.2.1.1. Delivery of Cytokines Gene
- 6.2.1.2. Delivery of Tumor Antigen Gene
- 6.2.2. Oncolytic Virotherapy
- 6.2.2.1. Adenovirus
- 6.2.2.2. Lentivirus
- 6.2.2.3. Retro Virus
- 6.2.2.4. Adeno Associated Virus
- 6.2.2.5. Herpes Simplex Virus
- 6.2.2.6. Alpha Virus
- 6.2.2.7. Vaccinia Virus
- 6.2.2.8. Simian Virus
- 6.2.2.9. Others
- 6.2.3. Gene Transfer
- 6.2.3.1. Naked/Plasmid Vectors
- 6.2.3.2. Electroporation
- 6.2.3.3. Sonoportion
- 6.2.3.4. Magnetofection
- 6.2.3.5. Gene Gun
- 6.2.1. Gene Induced Immunotherapy
- 6.3.1. Hospitals
- 6.3.2. Diagnostics Centers
- 6.3.3. Research Institutes
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Cancer Gene Therapy Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Therapy
- 7.2.1. Gene Induced Immunotherapy
- 7.2.1.1. Delivery of Cytokines Gene
- 7.2.1.2. Delivery of Tumor Antigen Gene
- 7.2.2. Oncolytic Virotherapy
- 7.2.2.1. Adenovirus
- 7.2.2.2. Lentivirus
- 7.2.2.3. Retro Virus
- 7.2.2.4. Adeno Associated Virus
- 7.2.2.5. Herpes Simplex Virus
- 7.2.2.6. Alpha Virus
- 7.2.2.7. Vaccinia Virus
- 7.2.2.8. Simian Virus
- 7.2.2.9. Others
- 7.2.3. Gene Transfer
- 7.2.3.1. Naked/Plasmid Vectors
- 7.2.3.2. Electroporation
- 7.2.3.3. Sonoportion
- 7.2.3.4. Magnetofection
- 7.2.3.5. Gene Gun
- 7.2.1. Gene Induced Immunotherapy
- 7.3.1. Hospitals
- 7.3.2. Diagnostics Centers
- 7.3.3. Research Institutes
- 7.4.1. UK
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Russia
- 7.4.7. Rest of Europe
8. Asia Pacific Cancer Gene Therapy Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Therapy
- 8.2.1. Gene Induced Immunotherapy
- 8.2.1.1. Delivery of Cytokines Gene
- 8.2.1.2. Delivery of Tumor Antigen Gene
- 8.2.2. Oncolytic Virotherapy
- 8.2.2.1. Adenovirus
- 8.2.2.2. Lentivirus
- 8.2.2.3. Retro Virus
- 8.2.2.4. Adeno Associated Virus
- 8.2.2.5. Herpes Simplex Virus
- 8.2.2.6. Alpha Virus
- 8.2.2.7. Vaccinia Virus
- 8.2.2.8. Simian Virus
- 8.2.2.9. Others
- 8.2.3. Gene Transfer
- 8.2.3.1. Naked/Plasmid Vectors
- 8.2.3.2. Electroporation
- 8.2.3.3. Sonoportion
- 8.2.3.4. Magnetofection
- 8.2.3.5. Gene Gun
- 8.2.1. Gene Induced Immunotherapy
- 8.3.1. Hospitals
- 8.3.2. Diagnostics Centers
- 8.3.3. Research Institutes
- 8.4.1. China
- 8.4.2. India
- 8.4.3. Japan
- 8.4.4. Australia
- 8.4.5. South East Asia
- 8.4.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Cancer Gene Therapy Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Therapy
- 9.2.1. Gene Induced Immunotherapy
- 9.2.1.1. Delivery of Cytokines Gene
- 9.2.1.2. Delivery of Tumor Antigen Gene
- 9.2.2. Oncolytic Virotherapy
- 9.2.2.1. Adenovirus
- 9.2.2.2. Lentivirus
- 9.2.2.3. Retro Virus
- 9.2.2.4. Adeno Associated Virus
- 9.2.2.5. Herpes Simplex Virus
- 9.2.2.6. Alpha Virus
- 9.2.2.7. Vaccinia Virus
- 9.2.2.8. Simian Virus
- 9.2.2.9. Others
- 9.2.3. Gene Transfer
- 9.2.3.1. Naked/Plasmid Vectors
- 9.2.3.2. Electroporation
- 9.2.3.3. Sonoportion
- 9.2.3.4. Magnetofection
- 9.2.3.5. Gene Gun
- 9.2.1. Gene Induced Immunotherapy
- 9.3.1. Hospitals
- 9.3.2. Diagnostics Centers
- 9.3.3. Research Institutes
- 9.4.1. Brazil
- 9.4.2. Saudi Arabia
- 9.4.3. UAE
- 9.4.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. Adaptimmune
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. ZioPharm Oncology Altor Bioscience
- 10.6. MolMed
- 10.7. bluebird bio
- 10.8. Shanghai Sunway Biotech company limited
- 10.9. MultiVir
- 10.10. Shenzhen SiBiono GeneTech, Corporation
- 10.11. GlaxoSmithKline
- 10.12. Merck
- 10.13. Celgene
- 10.14. BioCancell
- 10.15. SynerGene Therapeutics
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
